Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer [clinicaltrials:NCT00006034]
Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer [clinicaltrials:NCT00006034]
Bio2RDF identifier
NCT00006034
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00006034
identifiers.org URI
arm group [clinicaltrials_vocabulary:arm-group]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: Biological t ...... ents who cannot tolerate BCG.
brief title [clinicaltrials_vocabulary:brief-title]
Keyhole Limpet Hemocyanin Comp ...... g Patients With Bladder Cancer
completion date [clinicaltrials_vocabulary:completion-date]
2004-03-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES:
- ...... accrued for this
study.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2000-07-05T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
keyword [clinicaltrials_vocabulary:keyword]
recurrent bladder cancer
stage 0 bladder cancer
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2013-05-14T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00006034
number of arms [clinicaltrials_vocabulary:number-of-arms]
official title [clinicaltrials_vocabulary:official-title]
A Randomized, Multicenter Phas ...... icial Papillary Bladder Cancer
org study id [clinicaltrials_vocabulary:org-study-id]
INTRACEL-BCI-9804-04
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
secondary id [clinicaltrials_vocabulary:secondary-id]
CDR0000068047
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
1998-06-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2006-01-01T00:00:00Z
identifier
clinicaltrials:NCT00006034
title
Keyhole Limpet Hemocyanin Comp ...... g Patients With Bladder Cancer
@en
type
label
Keyhole Limpet Hemocyanin Comp ...... r [clinicaltrials:NCT00006034]
@en